An Mg-MOFs based multifunctional medicine for the treatment of osteoporotic pain.

Bone pain is the primary problem for patients with osteoporosis. Ketoprofen is clinically used to treat osteoporotic pain, while long-term oral administration of ketoprofen can cause some side effects. In addition, osteoporosis is also accompanied by bone mass loss and inflammation. In this study, we designed a multifunctional drug (Ket@Mg-MOF-74) adopted Mg-MOF-74 to load ketoprofen to treat osteoporotic pain, bone loss and inflammation comprehensively. Mg-MOF-74 was prepared, and the physicochemical characterization proved that it had excellent physical and chemical stability. Ket@Mg-MOF-74 was synthesized by post-synthetic modification method and a high loading rate of ketoprofen was confirmed. Drug release and ion release experiments indicated Ket@Mg-MOF-74 had a good controlled release of ketoprofen and Mg in solution. Cell experiments in vitro proved the compound drug could significantly reduce the expression of pain-related genes of cyclooxygenase 2 (COX2), obviously up-regulated the expression of osteogenic cytokines and remarkably down-regulated the secretion of pro-inflammatory factors. Therefore, Ket@Mg-MOF-74 is believed a promising painkiller for osteoporotic bone pain, with the function of anti-inflammatory and promoting bone formation. • A new medicine Ket@Mg-MOF-74 based on Mg-MOF-74 and ketoprofen was developed. • Mg-MOF-74 not only acts as a drug carrier but exhibits certain biological effects in the new medicine. • The Ket@Mg-MOF-74 can relief pain, inhibit inflammation and promote bone growth. • The Ket@Mg-MOF-74 should effectively treat osteoporotic pain and osteoporosis. [ABSTRACT FROM AUTHOR]